Brentuximab Vedotin Continues to Demonstrate Superior Clinical Activity - Onco'Zine
Updated and additional analysis of the ECHELON-1 and ECHELON-2 phase III frontline clinical trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), were presented during the annual meeting of the American Society of Clinical Oncology (ASCO), taking place May 31 to June 4, 2019 in Chicago, Ill.